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Background: Portal hypertension (PHT) requires invasive measures to prevent rupture and bleeding of
esophagogastric varices; however, the long-term results of subtotal splenectomy plus fixation of the retrosternal
omentum majus (SSFROM) have not been reported. Specifically, the advantages and disadvantages of surgery that
preserves the spleen and the long-term hematologic effects have not been described.
Study design: Our studies relating to SSFROM commenced in February 1999. As of April 2014 we have performed
256 subtotal splenectomies The records of 65 patients with PHT who underwent SSFROM were reviewed
retrospectively.
Results: Four patients died within 4 years of surgery, with a 4-year survival rate of 94 %; the 11-year survival rate
was 60 %. Eleven patients (17 %) had re-bleeding from esophagogastric varices. The white blood cell and platelet
counts were higher 6 and 11 years post-operatively compared with pre-operative values (P < 0.01). Portal venous
diameter, portal venous flow volume, splenic artery flow volume, as well as splenic length, thickness, and average
cross-sectional areas were shown to be significantly constricted or decreased (P < 0.01). The proportion of serum
CD3+ T cells, CD4+ T cells, and CD8+ T cells was increased (P < 0.01), while the serum levels of macrophage
colony-stimulating factor and granulocyte-macrophage colony-stimulating factor were significantly decreased
(P < 0.01). There was no significant change in the serum levels of IgA, IgM, IgG, and Tuftsin (P > 0.05). DSA
demonstrated that 15 cases formed collateral circulations between the portal vein and superior vena cava.
Conclusion: SSFROM provide long-term hemostasis for esophagogastric variceal bleeding in PHT and
corrected hypersplenism. SSFROM is an effective treatment for patients with PHT in whom long-term survival is
expected.
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The incidence of portal hypertension (PHT) with post-
hepatitis cirrhosis is higher in China than elsewhere
worldwide. PHT with concurrent esophagogastric vari-
ceal bleeding is one of the common causes of early
death [1]. Vein ligation under endoscopy and injection
sclerotherapy are the preferred hemostasis methods,
and bleeding control rates are 89.7 and 87.5 %, respect-
ively [2, 3]. A switch to decompressive shunt proce-
dures is mandatory if endoscopic therapy fails to
control recurrent variceal hemorrhage [4]. We rely on* Correspondence: jianhuazhaowf@163.com
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creativecommons.org/publicdomain/zero/1.0/bionics to devise a new technique to treat PTH with sub-
total splenectomy plus fixation of the retrosternal omen-
tum majus (SSFROM) [5]; however, this technique is
controversial. In the present study, the re-bleeding rate,
survival rate, hemodynamics, hematologic parameters,
splenic function, immunologic parameters, and related
indices were analyzed retrospectively to evaluate the long-
term efficacy of SSFROM in patients with PHT.Methods
Ethical approval of the study protocol (No. 1685) was
obtained from the Human Research Ethics Committee
of the 89th Hospital of PLA (Weifang, China). All indi-
viduals provided written informed consent before enroll-
ment in the study.le distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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Our studies relating to SSFROM commenced in Febru-
ary 1999. As of April 2014 we have performed 256 sub-
total splenectomies (preserving the lower pole, normal
spleen size of splenic tissue, splenic omentum, and
splenocolic vessels for the purpose of blood supply).
Sixty-five patients (34 males and 31 females; mean age,
34 years; age range, 25–43 years) with splenomegaly
due to PHT were randomly selected; 13 patients under-
went emergency surgery and 52 patients underwent
elective surgery. Liver biopsies were performed on all
patients to confirm cirrhosis. Twenty-three patients
had bleeding episodes prior to surgery and underwent
endoscopic injection sclerotherapy pre-operatively. Six
patients underwent six sessions of endoscopic injection
sclerotherapy. Patients were confirmed to have cirrhosis
after hepatitis-B infection, HBV-DNA was negative, and
were class A or B according to the Child–Pugh classifi-
cation. Cirrhosis was accompanied by hypersplenism
with moderate or severe varicose veins of the lower
esophagus, plus a history of digestive tract hemorrhage.
All patients were followed up continuously.
Operative method
A left upper abdominal “L” incision was made in the
abdomen to explore the liver and spleen. First, the lie-
norenal and splenophrenic ligaments were ligated.
Then, the spleen was moved through the incision. Sec-
ond, the gastrosplenic ligament and splenic artery stem
were ligated. The left gastroepiploic and splenocolic
vessels were preserved (Fig. 1a). Third, along the ische-
mic separatrix the subtotal spleen was removed; the
spleen bed was sutured by serous membranization.
Residual spleen, 11 × 7 × 4 cm in size, was preserved.
The residual splenic section was sutured using a hori-
zontal mattress cross-suture method (Fig. 1b). Fourth,
the splenic capsule was cauterized with an electrotome
to create a rough surface. Pericardial devascularization
was performed. Fifth, the omentum majus (10 × 5 cm
and 10 × 10 cm) was excised and the retrosternal space
was separated. A part of the omentum majus wasFig. 1 a The lienorenal and splenophrenic ligaments were ligated.
then, the gastrosplenic ligament and splenic artery stem were
ligated. The ischemic separatrix occurred obviously in spleen (arrow).
b The residual splenic section was sutured using a horizontal
mattress cross-suture method (arrow)tamponaded into the retrosternal space and fixed in
place. The residual spleen and the other omentum
majus were fixed into the retroperitoneum. Drainage
catheters were placed in the splenic recess, and the
abdominal cavity was closed.
Evaluation
The cumulative survival and non-bleeding rates were
determined by the Kaplan–Meier method. The portal
venous diameter, portal venous flow volume, and splenic
artery flow volume were detected by colour Doppler
sonography. The peripheral white blood cell and platelet
counts were measured using a hematology analyzer. An
abdominal CT scan measured the splenic size (splenic
length, splenic thickness, and splenic square area). Splenic
scintigraphy with 99mTc sulfur colloid evaluated the
phagocytic function of the residual spleen by ECT. The
serum CD3+ T cells, CD4+ T cells, and CD8+ T cells were
enumerated by flow cytometry. Serum macrophage colony-
stimulating factor (M-CSF) and granulocyte-macrophage
colony-stimulating factor (GM-CSF) were measured by
ELISA. Serum Tuftsin was measured with a radioimmu-
noanalyzer. Serum IgA, IgM, and IgG were measured
with a fully automatic biochemical immune analyzer.
Using digital subtraction angiography (DSA) through
an indwelling catheter in vessels of the omentum majus
post-operatively, the collateral vascular shunt between
the portal vein and superior vena cava was observed.
Statistical analyses
Data analyses were performed using SPSS (version 17.0;
SPSS, Inc., Chicago, IL, USA). All values are the mean ±
standard deviation. Groups were compared using a t-test. A
P < 0.05 was considered significant.
Results
Survival rate
The 4- and 11-year survival rates were 94 (61/65) and
60 % (39/65), respectively. Four patients died. Two
patients survived for 152 and 278 days. The cause of
death was complete occlusion of the portal vein as a
result of portal thrombosis. Two patients survived for 2
and 4 years. The cause of death was hepatic carcinoma
complicating liver failure (Fig. 2a).
Recurrent bleeding rate
Post-operative recurrent bleeding occurred in 11 pa-
tients (17 %), due to esophageal varices in eight patients
and from a gastric varix in three patients. All of the
patients were cured with conservative therapy. Of the 11
patients who bled post-operatively, seven had a history
of pre-operative bleeding and four were complicated
with portal thrombosis post-operatively. The 4- and
10-year non-bleeding rates were both 83 % (54/65;
Fig. 2 a Cumulative survival rates after subtotal splenectomy plus fixation of the retrosternal omentum majus (SSFROM) for portal hypertension (PHT).
The 4- and 11-year survival rates were 94 and 60 %. b Cumulative nonbleeding rates after SSFROM for PHT. Postoperative recurrent bleeding ccurred
in eleven patients (17 %). The 4- and 10-year non-bleeding rates were both 83 %
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variceal bleeding to data. Post-operative endoscopy of
the stomach showed exacerbation of esophagogastric
varices in 11 patients and prophylactic endoscopic in-
jection sclerotherapy was performed, after which nei-
ther re-bleeding nor re-exacerbation occurred. Portal
thrombosis occurred in six patients (9 %), from pre-
operative partial portal thrombosis and post-operative
exacerbation to complete occlusion of the portal vein
in two patients (Fig. 3).Change in peripheral blood cells
The white blood cell and platelet counts were associ-
ated with a significant rise 6 years post-operatively inFig. 3 CT scan showed that patients was complicated with portal
thrombosis at 4.5 months post-operatively48 patients and 11 years in 16 patients post-operatively
(P < 0.01; Fig. 4a).Change in hemodynamics of the splenic artery and portal
vein
There were significant differences between the pre- and
post-operative portal venous diameter, portal venous
flow volume, and splenic artery flow volume (P < 0.01;
Fig. 4b, c).Change in splenic volume
There were significant differences between the pre- and
post-operative splenic length, splenic thickness, and
splenic square area (P < 0.01; Fig. 4d, e).Change in immunologic and related indices
There were no significant differences between the IgA,
IgM, IgG, and Tuftsin levels pre- and post-operatively
(P > 0.05; Fig. 4f, g). The serum levels of M-CSF and GM-
CSF were decreased significantly, and there was a signifi-
cant difference between the pre- and post-operative values
(P < 0.01; Fig. 4 h). The proportion of CD3+ T cells, CD4+
T cells, and CD8+ T cells was increased post-operatively
compared with pre-operative values (P < 0.01; Fig. 4i).Change in splenic function
A CT scan revealed that the blood supply of the residual
spleen was normal (Fig. 5a, b). Isotope scanning with
99mTc showed that the residual splenic phagocytic func-
tion had recovered (Fig. 5c).
Fig. 4 a Changes in the white blood cell (WBC) count and platelet count at 6- and 11- years, after SSFROM for PHT (*P < 0.01). b Change in portal
venous diameter at 6- and 11- years, after SSFROM for PHT (*P < 0.01). c Changes in portal venous flow volume, and splenic artery flow volume at
6- and 11- years, after SSFROM for PHT (*P < 0.01). d Changes in splenic length and splenic thickness at 6- and 11- years, after SSFROM for PHT
(*P < 0.01). e Change in splenic square area. at 6- and 11- years, after SSFROM for PHT (*P < 0.01). f Changes in levels of serum IgA, IgM and IgG at
6 and 11 years, after SSFROM for PHT (*P > 0.05). g Change in levels of serum Tuftsin at 6 and 11 years, after SSFROM for PHT (*P > 0.05). h
Changes in levels of serum macrophage colony-stimulating factor (M-CSF) and granulocyte-macrophage colony-stimulating factor and (GM-CSF)
at 6 and 11 years, after SSFROM for PHT (*P < 0.01). i Changes in proportion of serum CD3+ T cells, CD4+ T cells, and CD8+ T cells at 6 and
11 years, after SSFROM for PHT (*P < 0.01)
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Fifteen patients had indwelling catheters placed in the
omental vein 1 month post-operatively. DSA showed
that omental venous blood flowed into the superior vena
cava. These results confirmed an established collateral
circulation between the portal vein and superior vena
cava (Fig. 5d).
Discussion
PHT is a clinical syndrome caused by the continual rise
in portal vein pressure, and is closely associated with the
incidence and mortality of chronic liver disease. The
severity of PHT is indicated by a hepatic portal venous
pressure gradient (difference between hepatic sinal por-
tal wedge pressure and free hepatic venous pressure) [6].
Under high pressure, reactive changes are observed in
the intra- and extra-hepatic vasculature, such as shear
stress, vascular proliferation, and neovascularization.
Collateral circulation plays an important role in buffer-
ing portal pressure [7]. Portal-systemic collateral vascu-
lar resistance and vasoconstrictor responsiveness arecrucial in PHT and control of variceal bleeding [8]. PHT
induces the formation of portal systemic collaterals.
Revealing the developmental change in portal-systemic
collaterals is important for future therapy [9]. The inci-
dence of gastric varices is 25 % and the rate of gastric
variceal hemorrhage is less than esophageal variceal
hemorrhage [10]. As PHT develops, the formation of
collateral vessels and arterial vasodilation progresses,
which results in increased blood flow to the portal circu-
lation [11]. The special anatomic structure of the esopha-
geal venous plexus results in easy, and even fatal, variceal
bleeding. According to statistics, esophageal varices are
detected in approximately 50 % of cirrhosis patients, and
5–15 % of cirrhotic patients have newly formed varices or
worsening of varices each year [12]. Thus, an understand-
ing of the pathogenesis of the collateral circulation and
compensatory mechanism in patients with PHT is crucial.
The spleen is the only solid organ of the portal venous
system. In patients with PHT, portal venous blood
returns flow and the splenic functions as an auxiliary
capacitance system which compensates for the increase
Fig. 5 a CT scan revealed splenomegaly pre-operatively. b CT scan revealed that the blood supply of the residual spleen was normal (arrow) at 1-year,
after SSFROM for PHT. c Isotope scanning with 99mTc showed that the residual splenic phagocytic function had recovered (arrow) at 4-years, after
SSFROM for PHT. d DSA showed an established collateral circulation between the portal vein and superior vena cava (arrow) at 1 month, after SSFROM
for PHT
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The splenic angiogenesis can regulate the portal sys-
temic collateral circulation and increase splenic blood
flow, which is a pathophysiologic hallmark of the spleen
[14, 15]. Traditionally, splenomegaly has been thought
to be due to passive splenic congestion. Recent research
suggests that factors of splenomegaly in portal hyperten-
sion include not only spleen congestion, as traditionally
thought, but also enlargement and hyperactivation of the
splenic lymphoid tissue, as well as increased angiogenesis
and fibrogenesis. Splenomegaly will not occur if the spon-
taneous portal systemic shunt exists. Therefore, portal
systemic collaterals and splenomegaly are the compensa-
tion of PHT. Of portal hypertensive patients with spleno-
megaly and hypersplenism, 64 % have a simultaneous
decrease in various blood cells, 36 % have a decrease in
single type blood cells, and 52 % of patients have bone
marrow hyperplasia. Therefore, a decrease in peripheral
blood cells and bone marrow hyperplasia are crucial indi-
ces of hypersplenism [16, 17]. In splenomegaly, the medial
ramus of perisplenic ligaments (lienorenal, splenophrenic,
and splenocolic ligaments) have abundant vessels, and
extensive collateral circulation is established between the
retroperitoneal space and pericardium, thus the spleen
can be called a “shunt bridge”. The major innovation of
the Warren operation utilizes the spleen as a shunt bridge,
which shunts blood flow to the stomach and spleen to
decrease pressure selectively [18].In general, vein ligation under endoscopy and injection
sclerotherapy are the preferred hematostatic method for
esophagogastric variceal bleeding, which have the advan-
tages of minimal trauma and rapid control of hemorrhage
compared with surgery; however, for some patients, the
long-term recurrent bleeding rate is higher than surgery
[19, 20]. For surgeons, the portosystemic shunt should be
performed after a transjugular intrahepatic portosystemic
shunt and before a liver transplantation [21]. In a study by
Orloff et al., [22] a portal-systemic shunt was used to treat
200 patients with portal vein thrombosis (extrahepatic
PHT). Actuarial 5-, 10-, and 15-year post-operative sur-
vival rates were 99 %, 97 %, and 95 %, respectively. No
patient developed portal-systemic encephalopathy. Gajin
et al., [23] compared different surgeries in PHT patients
and found that in the group of patients treated by distal
splenorenal shunt with partial spleen resection, only one
patient had splenomegaly post-operatively (5 %), while in
the group of patients treated by a distal splenorenal shunt
only, there were 13 patients with splenomegaly (68 %).
There was a significant statistical difference in platelet
count and splenic volume, which revealed that distal sple-
norenal shunt (Warren) plus partial spleen resection was
superior to the original Warren. Sretenovic et al., [24]
performed distal splenorenal shunts plus partial resection
of the spleen in 16 children with extrahepatic PHT. The
post-operative 2-year recurrent bleeding rate was 5 % and
the incidence of thrombosis was 7 %. This surgical
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PHT. Because of favorable liver function and without
cirrhosis, the post-operative long-term survival rate was
higher and the recurrent bleeding rate was lower. How-
ever, for patients with post-hepatitis cirrhosis, liver cancer
and liver failure may occur due to poor liver function and
the long-term survival rate decreased. However, for cir-
rhosis after hepatitis B infection, because of unfavorable
liver function, there was an increased probability for hepa-
tomas and liver failure, and the post-operative long-term
survival rate decreased. Therefore, the survival and recur-
rent bleeding rates depended on liver function.
SSFROM include the following. 1. Subtotal splenec-
tomy: The short gastric vessels and splenic artery stem
were ligated, preserving the lower splenic pole, and the
residual spleen was supplied by the left splenic omentum
and splenocolic vessels. The residual spleen and partial
omentum were fixed into the retroperitoneum. On the
one hand, the residual spleen can eliminate the high-
pressure state, and prevent recurrence of splenomegaly
and hypersplenism. On the other hand, as a bridge of
the portal-systemic shunt, the residual spleen can shunt
the high-pressure venous flow into the systemic circula-
tion. 2. Pericardial devascularization: Hemostasis of vas-
cular devascularization, especially the high esophageal
branch, which was crucial before the portal-systemic
shunt was established. 3. Fixation of the retrosternal
omentum majus: Collateral circulation was established
between the omentum majus and azygos vein; this de-
creases the bleeding risk of a natural portal-azygous
collateral pathway. Shunt flow volume can follow up the
portal pressure gradient and thoracic coeliac pressure
difference in self-regulation, without concern about sten-
osis of the anastomotic stoma and embolization occur-
ring. Post-operative DSA showed that the portal-azygous
collateral circulation was established. Color Doppler
ultrasound suggested that portal blood flow volume and
portal venous diameter have a significant constriction or
decrease compared with pre-operatively. The recurrent
bleeding rate was 17 % without hepatic encephalopathy.
It was revealed that this surgical technique has the long-
term effect of shunting, decreased pressure, and con-
trolled bleeding. The long-term follow-up of patients after
subtotal splenectomy showed that residual splenic blood
flow decreased; no residual splenic volume enlargement
occurred. Radioisotope scanning showed that residual
splenic phagocytosis was normal. Residual splenic immune
indices were the same as pre-operatively. Post-operative
peripheral white blood cell and platelet counts were associ-
ated with a significant pre-operative rise. Not only was the
residual splenic blood flow reduced, but hypersplenism was
corrected and residual splenic phagocytosis and immune
function still existed. The level of serum T lymphocyte sub-
population was higher and the level of serum M-CSF andGM-CSF was lower post-operatively compared with pre-
operatively. The results suggested that residual splenic
tissue of relieving high pressure can enhance the immune
reaction and weaken the inflammatory reaction. Our previ-
ous study showed that there was no significant difference
in the content of collagen, elasticity, and reticular fiber
between the residual spleen and splenomegaly. Electron
microscopy showed that the ultrastructure of lymphocytes
was improved. Immunohistochemical staining showed that
counts per unit area of T and B lymphocytes and macro-
phages increased markedly post-operatively compared with
pre-operatively [25, 26]. Thus, it can be seen that the ana-
tomic and physiologic foundation of subtotal splenectomy
provides valuable clinical information for splenic preserva-
tion. Our follow-up results (recurrent bleeding rate, and
hemodynamic, hematologic, and immunologic indices)
were nearly in agreement with that reported by Hase et
al [27]. There is a difference in survival rate, which may
be caused by different liver function. Hemorrhoidal bleed-
ing was not observed in our study. Our data showed that
the major reasons for massive post-operative bleeding
were as follows: 1. In the short-term, collateral circulation
was not established between the portal and azygos veins,
and the portal venous pressure of the patients after
disconnection showed a transient increase. and 2. After
disconnection, blood flow to the lower esophagus and
gastric wall had a high dynamic state, which induced a
submucosal arteriovenous shunt, mucosal ischemia, hypo-
function of the barrier, and formed the pathogenic basis of
mucosal lesions. Our data also showed that the incidence
of post-operative portal thrombosis was 9 %, which was
lower than other reports [28–32]. The analyses were re-
lated to protection of the partial spleen and administration
of a corresponding anticoagulant measure(low-molecular
weight heparin calcium [5000 U subcutaneously] starting
on the 2nd day after surgery (daily for 2 weeks). Then,
warfarin or rivaroxaban was taken orally once a day for
3 months). In the current study, the patients with post-
operative portal thromboses were treated with anticoagu-
lation and antiagglutinating as well as thrombolysis, and
was absorbed completely or the improvement of absorp-
tion within 2-4 weeks. In our opinion, compared with the
Warren operation, SSFROM is a simple operation, is easy
to popularize, and can obtain the same clinical effect;
therefore it is worth popularizing. However, it must be
emphasized that the patients in this study were select
patients, class A or B according to the Child–Pugh classi-
fication, and controlled content of the virus can improve
the long-term survival rate.Conclusion
SSFROM provides long-term hemostasis for esophagogas-
tric variceal bleeding in PHT and corrects hypersplenism.
Chu et al. BMC Surgery  (2015) 15:89 Page 7 of 7SSFROM is an effective treatment for patients with PHT
in whom long-term survival is expected.
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